Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.53 |
| ▸ | ABL1 | P00519 | 3/20 | 0.53 |
| ▸ | ABL2 | P42684 | 2/20 | 0.53 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.45 |
| ▸ | FLT1 | P17948 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7497953 | 0.89 | EGFR (0.54) | EGFRABL1ABL2SRCMKNK1 | |
| SCHEMBL8088017 | 0.88 | MKNK1 (0.54) | EGFRABL1ABL2SRCABCG2 | |
| SCHEMBL8088051 | 0.79 | MEN1 (0.63) | EGFRABL1ABL2SRCPDGFRB | |
| SCHEMBL3254913 | 0.76 | ABCC1 (0.43) | ABCG2ALDH1A1 | |
| SCHEMBL7494710 | 0.76 | MEN1 (0.56) | — | |
| SCHEMBL8016721 | 0.75 | SLC2A1 (0.49) | ALDH1A1 | |
| SCHEMBL17406910 | 0.75 | TSHR (0.57) | — | |
| SCHEMBL3262074 | 0.73 | MEN1 (0.47) | ABCG2ALDH1A1MAPT | |
| SCHEMBL3257221 | 0.73 | MAPK14 (0.41) | — | |
| SCHEMBL13064037 | 0.73 | EGFR (0.53) | EGFRABL1SRCMKNK1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6096749-A | ANTITUMOR, EPIDERMAL GROWTH FACTOR | NOVARTIS CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0682027-B1 | Pyrrolopyrimidine derivatives with antiproliferative action | CIBA GEIGY AG (CH) | 1997-10-15 | — | — | EP | disclosed |
| EP-0682027-A1 | Pyrrolopyrimidine derivatives with antiproliferative action | CIBA-GEIGY AG (CH) | 1995-11-15 | — | — | EP | disclosed |